- Current report filing (8-K)
August 02 2011 - 1:27PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): August 2, 2011
MAP PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-33719
|
|
20-0507047
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
2400 Bayshore Parkway, Suite 200, Mountain
View, CA
|
|
94043
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 386-3100
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On August 2, 2011, MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) (the Company) announced that the Companys New Drug Application (NDA) for LEVADEX
®
orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by
the U.S. Food and Drug Administration. The Company also announced that the acceptance for filing of the LEVADEX NDA triggers a milestone payment to the Company by Allergan, Inc. pursuant to the terms of the Collaboration Agreement between the
Company, Allergan, Inc. and Allergan Sales LLC dated January 28, 2011.
The Company announced the acceptance for filing
of the NDA in a press release that is attached hereto as Exhibit 99.1
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated August 2, 2011
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: August 2, 2011
|
|
MAP PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
|
/s/ Charlene A. Friedman
|
|
|
Name:
|
|
Charlene A. Friedman
|
|
|
Title:
|
|
Senior Vice President, General Counsel and Secretary
|
INDEX TO EXHIBITS FILED WITH
THE CURRENT REPORT ON FORM 8-K DATED AUGUST 2, 2011
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated August 2, 2011
|
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Jul 2023 to Jul 2024